A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Recruiting · NCT06907043 · Registry updated 2025-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. | Neoplasms by Site, brain disorder, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder | Recruiting | Phase 1 / Phase 2 | 2025-08-19 | NCT06907043 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eikon Therapeutics | 7 |
| Impact Therapeutics, Inc. | 4 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital) | Jinan | China | 4 |
| Chongqing University Cancer Hospital | Chongqing | China | 54 |
| Florida Cancer Center | Lake Mary | United States | 1 |
| Fudan University Shanghai Cancer Center | Shanghai | China | 128 |
| MD Anderson | Houston | United States | 56 |
| NEXT Oncology | San Antonio | United States | 70 |
| NEXT Virginia | Fairfax | United States | 83 |
| PASO Medical | Frankston | Australia | 3 |
| Sarah Cannon Research Institute at HealthOne | Denver | United States | 34 |